KR20090125857A - 흡입용 조성물 - Google Patents
흡입용 조성물 Download PDFInfo
- Publication number
- KR20090125857A KR20090125857A KR1020097024298A KR20097024298A KR20090125857A KR 20090125857 A KR20090125857 A KR 20090125857A KR 1020097024298 A KR1020097024298 A KR 1020097024298A KR 20097024298 A KR20097024298 A KR 20097024298A KR 20090125857 A KR20090125857 A KR 20090125857A
- Authority
- KR
- South Korea
- Prior art keywords
- pvp
- formoterol
- peg
- budesonide
- suspension
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Ceased
Links
- 239000000203 mixture Substances 0.000 title abstract description 34
- YFMFNYKEUDLDTL-UHFFFAOYSA-N 1,1,1,2,3,3,3-heptafluoropropane Chemical compound FC(F)(F)C(F)C(F)(F)F YFMFNYKEUDLDTL-UHFFFAOYSA-N 0.000 claims abstract description 6
- 208000023504 respiratory system disease Diseases 0.000 claims abstract description 6
- BPZSYCZIITTYBL-UHFFFAOYSA-N formoterol Chemical compound C1=CC(OC)=CC=C1CC(C)NCC(O)C1=CC=C(O)C(NC=O)=C1 BPZSYCZIITTYBL-UHFFFAOYSA-N 0.000 claims description 19
- 229960002848 formoterol Drugs 0.000 claims description 19
- VOVIALXJUBGFJZ-KWVAZRHASA-N Budesonide Chemical compound C1CC2=CC(=O)C=C[C@]2(C)[C@@H]2[C@@H]1[C@@H]1C[C@H]3OC(CCC)O[C@@]3(C(=O)CO)[C@@]1(C)C[C@@H]2O VOVIALXJUBGFJZ-KWVAZRHASA-N 0.000 claims description 15
- 229960004436 budesonide Drugs 0.000 claims description 15
- 238000000034 method Methods 0.000 claims description 13
- 239000008194 pharmaceutical composition Substances 0.000 claims description 5
- 241000124008 Mammalia Species 0.000 claims 1
- WHNWPMSKXPGLAX-UHFFFAOYSA-N N-Vinyl-2-pyrrolidone Chemical compound C=CN1CCCC1=O WHNWPMSKXPGLAX-UHFFFAOYSA-N 0.000 claims 1
- 238000009472 formulation Methods 0.000 abstract description 29
- 229920000036 polyvinylpyrrolidone Polymers 0.000 abstract description 21
- LYCAIKOWRPUZTN-UHFFFAOYSA-N Ethylene glycol Chemical compound OCCO LYCAIKOWRPUZTN-UHFFFAOYSA-N 0.000 abstract description 18
- 229920002523 polyethylene Glycol 1000 Polymers 0.000 abstract description 18
- 229920003080 Povidone K 25 Polymers 0.000 abstract description 12
- 229920001223 polyethylene glycol Polymers 0.000 abstract description 11
- 229940021598 formoterol and budesonide Drugs 0.000 abstract description 4
- 239000000725 suspension Substances 0.000 description 27
- 235000013855 polyvinylpyrrolidone Nutrition 0.000 description 20
- 239000001267 polyvinylpyrrolidone Substances 0.000 description 20
- 239000000523 sample Substances 0.000 description 11
- 239000002202 Polyethylene glycol Substances 0.000 description 10
- 238000012360 testing method Methods 0.000 description 8
- 238000002834 transmittance Methods 0.000 description 8
- PJFHZKIDENOSJB-UHFFFAOYSA-N Budesonide/formoterol Chemical compound C1=CC(OC)=CC=C1CC(C)NCC(O)C1=CC=C(O)C(NC=O)=C1.C1CC2=CC(=O)C=CC2(C)C2C1C1CC3OC(CCC)OC3(C(=O)CO)C1(C)CC2O PJFHZKIDENOSJB-UHFFFAOYSA-N 0.000 description 7
- 239000006185 dispersion Substances 0.000 description 7
- 229940080593 budesonide / formoterol Drugs 0.000 description 6
- 238000011156 evaluation Methods 0.000 description 6
- 230000035699 permeability Effects 0.000 description 6
- 238000011084 recovery Methods 0.000 description 6
- NWLPAIVRIWBEIT-SEPHDYHBSA-N (e)-but-2-enedioic acid;dihydrate Chemical compound O.O.OC(=O)\C=C\C(O)=O NWLPAIVRIWBEIT-SEPHDYHBSA-N 0.000 description 5
- 229920000139 polyethylene terephthalate Polymers 0.000 description 5
- 239000005020 polyethylene terephthalate Substances 0.000 description 5
- 239000000047 product Substances 0.000 description 5
- 230000005540 biological transmission Effects 0.000 description 4
- 238000012512 characterization method Methods 0.000 description 4
- 239000007788 liquid Substances 0.000 description 4
- 239000002245 particle Substances 0.000 description 4
- 238000001556 precipitation Methods 0.000 description 4
- 150000003839 salts Chemical class 0.000 description 4
- 230000035945 sensitivity Effects 0.000 description 4
- PJFHZKIDENOSJB-JIVDDGRNSA-N symbicort inhalation aerosol Chemical compound C1=CC(OC)=CC=C1C[C@H](C)NC[C@@H](O)C1=CC=C(O)C(NC=O)=C1.C1CC2=CC(=O)C=C[C@]2(C)[C@@H]2[C@@H]1[C@@H]1C[C@H]3OC(CCC)O[C@@]3(C(=O)CO)[C@@]1(C)C[C@@H]2O PJFHZKIDENOSJB-JIVDDGRNSA-N 0.000 description 4
- 208000006545 Chronic Obstructive Pulmonary Disease Diseases 0.000 description 3
- 239000004480 active ingredient Substances 0.000 description 3
- 208000006673 asthma Diseases 0.000 description 3
- 230000008859 change Effects 0.000 description 3
- 230000000694 effects Effects 0.000 description 3
- 238000005259 measurement Methods 0.000 description 3
- 229940071648 metered dose inhaler Drugs 0.000 description 3
- 238000007557 optical granulometry Methods 0.000 description 3
- 206010039083 rhinitis Diseases 0.000 description 3
- 239000012453 solvate Substances 0.000 description 3
- HBAQYPYDRFILMT-UHFFFAOYSA-N 8-[3-(1-cyclopropylpyrazol-4-yl)-1H-pyrazolo[4,3-d]pyrimidin-5-yl]-3-methyl-3,8-diazabicyclo[3.2.1]octan-2-one Chemical class C1(CC1)N1N=CC(=C1)C1=NNC2=C1N=C(N=C2)N1C2C(N(CC1CC2)C)=O HBAQYPYDRFILMT-UHFFFAOYSA-N 0.000 description 2
- 238000004458 analytical method Methods 0.000 description 2
- 150000001875 compounds Chemical class 0.000 description 2
- 238000012937 correction Methods 0.000 description 2
- 238000010586 diagram Methods 0.000 description 2
- 238000012377 drug delivery Methods 0.000 description 2
- 208000027866 inflammatory disease Diseases 0.000 description 2
- 210000004072 lung Anatomy 0.000 description 2
- 230000003287 optical effect Effects 0.000 description 2
- 238000002360 preparation method Methods 0.000 description 2
- 230000002265 prevention Effects 0.000 description 2
- 230000008569 process Effects 0.000 description 2
- -1 tricarvalates Chemical class 0.000 description 2
- UPHOPMSGKZNELG-UHFFFAOYSA-N 2-hydroxynaphthalene-1-carboxylic acid Chemical class C1=CC=C2C(C(=O)O)=C(O)C=CC2=C1 UPHOPMSGKZNELG-UHFFFAOYSA-N 0.000 description 1
- FJKROLUGYXJWQN-UHFFFAOYSA-M 4-hydroxybenzoate Chemical compound OC1=CC=C(C([O-])=O)C=C1 FJKROLUGYXJWQN-UHFFFAOYSA-M 0.000 description 1
- ZEYHEAKUIGZSGI-UHFFFAOYSA-N 4-methoxybenzoic acid Chemical compound COC1=CC=C(C(O)=O)C=C1 ZEYHEAKUIGZSGI-UHFFFAOYSA-N 0.000 description 1
- CPELXLSAUQHCOX-UHFFFAOYSA-M Bromide Chemical compound [Br-] CPELXLSAUQHCOX-UHFFFAOYSA-M 0.000 description 1
- VEXZGXHMUGYJMC-UHFFFAOYSA-M Chloride anion Chemical compound [Cl-] VEXZGXHMUGYJMC-UHFFFAOYSA-M 0.000 description 1
- KRKNYBCHXYNGOX-UHFFFAOYSA-K Citrate Chemical compound [O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O KRKNYBCHXYNGOX-UHFFFAOYSA-K 0.000 description 1
- OCUCCJIRFHNWBP-IYEMJOQQSA-L Copper gluconate Chemical class [Cu+2].OC[C@@H](O)[C@@H](O)[C@H](O)[C@@H](O)C([O-])=O.OC[C@@H](O)[C@@H](O)[C@H](O)[C@@H](O)C([O-])=O OCUCCJIRFHNWBP-IYEMJOQQSA-L 0.000 description 1
- FEWJPZIEWOKRBE-JCYAYHJZSA-N Dextrotartaric acid Chemical compound OC(=O)[C@H](O)[C@@H](O)C(O)=O FEWJPZIEWOKRBE-JCYAYHJZSA-N 0.000 description 1
- 150000000994 L-ascorbates Chemical class 0.000 description 1
- 229910019142 PO4 Inorganic materials 0.000 description 1
- QAOWNCQODCNURD-UHFFFAOYSA-L Sulfate Chemical compound [O-]S([O-])(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-L 0.000 description 1
- 150000001242 acetic acid derivatives Chemical class 0.000 description 1
- 235000010323 ascorbic acid Nutrition 0.000 description 1
- 230000008901 benefit Effects 0.000 description 1
- SRSXLGNVWSONIS-UHFFFAOYSA-N benzenesulfonic acid Chemical class OS(=O)(=O)C1=CC=CC=C1 SRSXLGNVWSONIS-UHFFFAOYSA-N 0.000 description 1
- WPYMKLBDIGXBTP-UHFFFAOYSA-N benzoic acid Chemical compound OC(=O)C1=CC=CC=C1 WPYMKLBDIGXBTP-UHFFFAOYSA-N 0.000 description 1
- 239000006227 byproduct Substances 0.000 description 1
- 239000006071 cream Substances 0.000 description 1
- WBGKWQHBNHJJPZ-LECWWXJVSA-N desonide Chemical compound C1CC2=CC(=O)C=C[C@]2(C)[C@@H]2[C@@H]1[C@@H]1C[C@H]3OC(C)(C)O[C@@]3(C(=O)CO)[C@@]1(C)C[C@@H]2O WBGKWQHBNHJJPZ-LECWWXJVSA-N 0.000 description 1
- 229960003662 desonide Drugs 0.000 description 1
- 230000001687 destabilization Effects 0.000 description 1
- 238000001514 detection method Methods 0.000 description 1
- 238000011161 development Methods 0.000 description 1
- 201000010099 disease Diseases 0.000 description 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 1
- 229940079593 drug Drugs 0.000 description 1
- 239000003814 drug Substances 0.000 description 1
- 239000000839 emulsion Substances 0.000 description 1
- 150000002148 esters Chemical class 0.000 description 1
- 239000012458 free base Substances 0.000 description 1
- 239000011521 glass Substances 0.000 description 1
- JFCQEDHGNNZCLN-UHFFFAOYSA-N glutaric acid Chemical class OC(=O)CCCC(O)=O JFCQEDHGNNZCLN-UHFFFAOYSA-N 0.000 description 1
- 150000003893 lactate salts Chemical class 0.000 description 1
- VZCYOOQTPOCHFL-UPHRSURJSA-N maleic acid Chemical compound OC(=O)\C=C/C(O)=O VZCYOOQTPOCHFL-UPHRSURJSA-N 0.000 description 1
- 238000013508 migration Methods 0.000 description 1
- 230000005012 migration Effects 0.000 description 1
- 239000000546 pharmaceutical excipient Substances 0.000 description 1
- 239000000825 pharmaceutical preparation Substances 0.000 description 1
- 229940127557 pharmaceutical product Drugs 0.000 description 1
- NBIIXXVUZAFLBC-UHFFFAOYSA-K phosphate Chemical compound [O-]P([O-])([O-])=O NBIIXXVUZAFLBC-UHFFFAOYSA-K 0.000 description 1
- 239000010452 phosphate Substances 0.000 description 1
- 239000000843 powder Substances 0.000 description 1
- 239000003380 propellant Substances 0.000 description 1
- 238000011002 quantification Methods 0.000 description 1
- 230000000241 respiratory effect Effects 0.000 description 1
- YGSDEFSMJLZEOE-UHFFFAOYSA-M salicylate Chemical compound OC1=CC=CC=C1C([O-])=O YGSDEFSMJLZEOE-UHFFFAOYSA-M 0.000 description 1
- 150000003890 succinate salts Chemical class 0.000 description 1
- 229940035073 symbicort Drugs 0.000 description 1
- 229940095064 tartrate Drugs 0.000 description 1
- JOXIMZWYDAKGHI-UHFFFAOYSA-N toluene-4-sulfonic acid Chemical class CC1=CC=C(S(O)(=O)=O)C=C1 JOXIMZWYDAKGHI-UHFFFAOYSA-N 0.000 description 1
- VZCYOOQTPOCHFL-UHFFFAOYSA-N trans-butenedioic acid Natural products OC(=O)C=CC(O)=O VZCYOOQTPOCHFL-UHFFFAOYSA-N 0.000 description 1
- 238000005303 weighing Methods 0.000 description 1
Images
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
- A61K31/58—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids containing heterocyclic rings, e.g. danazol, stanozolol, pancuronium or digitogenin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/16—Amides, e.g. hydroxamic acids
- A61K31/165—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide
- A61K31/167—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide having the nitrogen of a carboxamide group directly attached to the aromatic ring, e.g. lidocaine, paracetamol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
- A61K31/19—Carboxylic acids, e.g. valproic acid
- A61K31/194—Carboxylic acids, e.g. valproic acid having two or more carboxyl groups, e.g. succinic, maleic or phthalic acid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
- A61K31/57—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone
- A61K31/573—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone substituted in position 21, e.g. cortisone, dexamethasone, prednisone or aldosterone
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
- A61K47/32—Macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. carbomers, poly(meth)acrylates, or polyvinyl pyrrolidone
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
- A61K47/34—Macromolecular compounds obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyesters, polyamino acids, polysiloxanes, polyphosphazines, copolymers of polyalkylene glycol or poloxamers
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/007—Pulmonary tract; Aromatherapy
- A61K9/0073—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy
- A61K9/008—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy comprising drug dissolved or suspended in liquid propellant for inhalation via a pressurized metered dose inhaler [MDI]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/02—Nasal agents, e.g. decongestants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/06—Antiasthmatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/08—Bronchodilators
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Medicinal Chemistry (AREA)
- Veterinary Medicine (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Epidemiology (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Pulmonology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Otolaryngology (AREA)
- Pain & Pain Management (AREA)
- Inorganic Chemistry (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicinal Preparation (AREA)
- Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Pyrane Compounds (AREA)
- Stabilization Of Oscillater, Synchronisation, Frequency Synthesizers (AREA)
- Networks Using Active Elements (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| SE0200312-7 | 2002-02-01 | ||
| SE0200312A SE0200312D0 (sv) | 2002-02-01 | 2002-02-01 | Novel composition |
Related Parent Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| KR1020047011787A Division KR100947168B1 (ko) | 2002-02-01 | 2003-01-29 | 흡입용 조성물 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| KR20090125857A true KR20090125857A (ko) | 2009-12-07 |
Family
ID=20286853
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| KR1020047011787A Expired - Lifetime KR100947168B1 (ko) | 2002-02-01 | 2003-01-29 | 흡입용 조성물 |
| KR1020097024298A Ceased KR20090125857A (ko) | 2002-02-01 | 2003-01-29 | 흡입용 조성물 |
Family Applications Before (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| KR1020047011787A Expired - Lifetime KR100947168B1 (ko) | 2002-02-01 | 2003-01-29 | 흡입용 조성물 |
Country Status (27)
| Country | Link |
|---|---|
| US (8) | US7759328B2 (enExample) |
| EP (2) | EP1474117B1 (enExample) |
| JP (2) | JP2005521663A (enExample) |
| KR (2) | KR100947168B1 (enExample) |
| CN (1) | CN1287774C (enExample) |
| AT (2) | ATE463241T1 (enExample) |
| AU (1) | AU2003206289B2 (enExample) |
| BR (1) | BR0307193A (enExample) |
| CA (1) | CA2474479C (enExample) |
| CO (1) | CO5611098A2 (enExample) |
| CY (2) | CY1109030T1 (enExample) |
| DE (2) | DE60332067D1 (enExample) |
| DK (2) | DK2036549T3 (enExample) |
| ES (2) | ES2321180T3 (enExample) |
| IL (1) | IL163160A (enExample) |
| IS (2) | IS7360A (enExample) |
| MX (1) | MXPA04007295A (enExample) |
| NO (1) | NO337006B1 (enExample) |
| NZ (1) | NZ534452A (enExample) |
| PL (1) | PL211836B1 (enExample) |
| PT (2) | PT1474117E (enExample) |
| RU (1) | RU2301673C2 (enExample) |
| SE (1) | SE0200312D0 (enExample) |
| SI (2) | SI1474117T1 (enExample) |
| UA (1) | UA79445C2 (enExample) |
| WO (1) | WO2003063842A1 (enExample) |
| ZA (1) | ZA200406086B (enExample) |
Cited By (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| KR20200024102A (ko) | 2018-08-27 | 2020-03-06 | 데이진 가부시키가이샤 | 극세 탄소 섬유 혼합물, 그 제조 방법, 및 탄소계 도전 보조제 |
Families Citing this family (40)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| SE0200312D0 (sv) * | 2002-02-01 | 2002-02-01 | Astrazeneca Ab | Novel composition |
| US9084799B2 (en) | 2005-02-11 | 2015-07-21 | Pulmagen Therapeutics (Synergy) Limited | Inhaled combination therapy |
| WO2006085102A1 (en) * | 2005-02-11 | 2006-08-17 | Argenta Discovery Limited | Combination of methylxanthine compounds and steroids to treat chronic respiratory diseases |
| DE102006053374A1 (de) * | 2006-02-09 | 2007-08-16 | Boehringer Ingelheim Pharma Gmbh & Co. Kg | Pharmazeutische Formulierung für Aerosole mit zwei oder mehr Wirkstoffen und mindestens einer oberflächenaktiven Substanz |
| GB0604141D0 (en) * | 2006-03-01 | 2006-04-12 | Arrow Int Ltd | Nebulizer formulation |
| GB0712454D0 (en) * | 2007-06-27 | 2007-08-08 | Generics Uk Ltd | Pharmaceutical compositions |
| EP2077132A1 (en) | 2008-01-02 | 2009-07-08 | Boehringer Ingelheim Pharma GmbH & Co. KG | Dispensing device, storage device and method for dispensing a formulation |
| US20130160761A1 (en) * | 2008-11-04 | 2013-06-27 | Cipla Limited | Pharmaceutical Aerosol Composition |
| NZ574666A (en) * | 2009-02-05 | 2009-04-30 | Nexus6 Ltd | A medicament inhaler holder that uses optical means to count and display the number of doses used |
| EP2662472B1 (de) | 2009-03-31 | 2019-02-27 | Boehringer Ingelheim International Gmbh | Verfahren zur Beschichtung einer Oberfläche eines Bauteils |
| US9265910B2 (en) | 2009-05-18 | 2016-02-23 | Boehringer Ingelheim International Gmbh | Adapter, inhalation device, and nebulizer |
| US10016568B2 (en) | 2009-11-25 | 2018-07-10 | Boehringer Ingelheim International Gmbh | Nebulizer |
| WO2011064163A1 (en) | 2009-11-25 | 2011-06-03 | Boehringer Ingelheim International Gmbh | Nebulizer |
| EP2504052B1 (en) | 2009-11-25 | 2022-07-27 | Boehringer Ingelheim International GmbH | Nebulizer |
| JP5874724B2 (ja) | 2010-06-24 | 2016-03-02 | ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング | ネブライザ |
| CN110237260A (zh) * | 2010-07-16 | 2019-09-17 | 希普拉有限公司 | 包含r(+)布地奈德和一种或多种支气管扩张剂的药物组合物 |
| BR112013002504A2 (pt) * | 2010-08-03 | 2016-05-31 | Chiesi Farma Spa | formulação farmacêutica para administração em aerosol, inalador pressurizado dosimetrado (pmdi), formulação farmacêutica para nebulização, frasco de dose única ou múltiplas e uso de uma formulação |
| CA2812263A1 (en) * | 2010-09-22 | 2012-03-29 | Map Pharmaceuticals, Inc. | Corticosteroid particles and method of production |
| US20120204871A1 (en) | 2011-02-10 | 2012-08-16 | Julio Cesar Vega | Stable, non-corrosive formulations for pressurized metered dose inhalers |
| TWI399202B (zh) * | 2011-03-17 | 2013-06-21 | Intech Biopharm Ltd | 製備用於治療呼吸道疾病之定量噴霧吸入劑的製程方法 |
| EP2694220B1 (de) | 2011-04-01 | 2020-05-06 | Boehringer Ingelheim International GmbH | Medizinisches gerät mit behälter |
| US9827384B2 (en) | 2011-05-23 | 2017-11-28 | Boehringer Ingelheim International Gmbh | Nebulizer |
| PH12014500440A1 (en) | 2011-08-19 | 2014-04-28 | Intech Biopharm Ltd | Method for preparing metered dose sprayed inhaler for treating respiratory disease |
| WO2013152894A1 (de) | 2012-04-13 | 2013-10-17 | Boehringer Ingelheim International Gmbh | Zerstäuber mit kodiermitteln |
| US9744313B2 (en) | 2013-08-09 | 2017-08-29 | Boehringer Ingelheim International Gmbh | Nebulizer |
| PL2835146T3 (pl) | 2013-08-09 | 2021-04-06 | Boehringer Ingelheim International Gmbh | Nebulizator |
| GB201321712D0 (en) | 2013-12-09 | 2014-01-22 | Pharmachemie Bv | Dry Powder Inhaler |
| GB201321717D0 (en) | 2013-12-09 | 2014-01-22 | Pharmachemie Bv | Inhalable Medicaments |
| EP3139984B1 (en) | 2014-05-07 | 2021-04-28 | Boehringer Ingelheim International GmbH | Nebulizer |
| TWI607770B (zh) | 2014-05-07 | 2017-12-11 | 百靈佳殷格翰國際股份有限公司 | 噴霧器及其容器 |
| PL3139979T3 (pl) | 2014-05-07 | 2023-12-27 | Boehringer Ingelheim International Gmbh | Jednostka, nebulizator i sposób |
| WO2016018892A1 (en) | 2014-07-29 | 2016-02-04 | 3M Innovative Properties Company | Method of preparing a pharmaceutical composition |
| CN108289843B (zh) | 2015-12-04 | 2021-08-17 | 墨西哥氟石股份公司 | 药物组合物 |
| CN106581010B (zh) * | 2016-12-28 | 2019-03-05 | 四川普锐特医药科技有限责任公司 | 一种气溶胶制剂及定量吸入气雾剂 |
| AU2018318123B2 (en) | 2017-08-15 | 2024-07-25 | Nephron Pharmaceuticals Corporation | Aqueous nebulization composition |
| AU2019287541A1 (en) | 2018-06-14 | 2021-01-21 | Astrazeneca Uk Limited | Methods for treating and preventing symptoms of asthma with a corticosteroid pharmaceutical composition |
| CN109464429B (zh) * | 2018-12-13 | 2021-04-27 | 上海方予健康医药科技有限公司 | 一种吸入压力定量气雾剂药物组合物及其制备方法 |
| CN112137957B (zh) | 2019-06-26 | 2022-07-29 | 长风药业股份有限公司 | 一种药用吸入气雾剂及其制备方法 |
| CN112972384B (zh) * | 2019-12-02 | 2022-03-18 | 长风药业股份有限公司 | 一种格隆溴铵和茚达特罗原料药微粉混合物的制备方法 |
| CN117357485B (zh) * | 2023-11-01 | 2024-09-24 | 山东京卫制药有限公司 | 一种改良的可吸入的载体颗粒及应用 |
Family Cites Families (18)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US6123924A (en) * | 1991-09-25 | 2000-09-26 | Fisons Plc | Pressurized aerosol inhalation compositions |
| IL103238A (en) * | 1991-09-25 | 1995-07-31 | Fisons Plc | Pressurised aerosol compositions |
| WO1993011773A1 (en) | 1991-12-18 | 1993-06-24 | Aktiebolaget Astra | New combination of formoterol and budesonide |
| DE19536902A1 (de) * | 1995-10-04 | 1997-04-10 | Boehringer Ingelheim Int | Vorrichtung zur Hochdruckerzeugung in einem Fluid in Miniaturausführung |
| SE9603669D0 (sv) | 1996-10-08 | 1996-10-08 | Astra Ab | New combination |
| PT938467E (pt) * | 1996-11-11 | 2002-11-29 | Sepracor Inc | Processo para a preparacao de isomeros opticamente puros de formoterol |
| SE9703407D0 (sv) * | 1997-09-19 | 1997-09-19 | Astra Ab | New use |
| US6309623B1 (en) * | 1997-09-29 | 2001-10-30 | Inhale Therapeutic Systems, Inc. | Stabilized preparations for use in metered dose inhalers |
| SE9802073D0 (sv) * | 1998-06-11 | 1998-06-11 | Astra Ab | New use |
| US6585958B1 (en) | 1998-07-24 | 2003-07-01 | Jago Research Ag | Medicinal aerosol formulations |
| US6004537A (en) | 1998-12-18 | 1999-12-21 | Baker Norton Pharmaceuticals, Inc. | Pharmaceutical solution aerosol formulations containing fluoroalkanes, budesonide and formoterol |
| SE9900834D0 (sv) | 1999-03-09 | 1999-03-09 | Astra Ab | Novel combination |
| PE20011227A1 (es) | 2000-04-17 | 2002-01-07 | Chiesi Farma Spa | Formulaciones farmaceuticas para inhaladores de polvo seco en la forma de aglomerados duros |
| GB0009584D0 (en) | 2000-04-18 | 2000-06-07 | Glaxo Group Ltd | Pharmaceutical compositions |
| GB0012260D0 (en) * | 2000-05-19 | 2000-07-12 | Astrazeneca Ab | Novel composition |
| GB0016876D0 (en) | 2000-07-11 | 2000-08-30 | Astrazeneca Ab | Novel formulation |
| US20030018019A1 (en) * | 2001-06-23 | 2003-01-23 | Boehringer Ingelheim Pharma Kg | Pharmaceutical compositions based on anticholinergics, corticosteroids and betamimetics |
| SE0200312D0 (sv) * | 2002-02-01 | 2002-02-01 | Astrazeneca Ab | Novel composition |
-
2002
- 2002-02-01 SE SE0200312A patent/SE0200312D0/xx unknown
-
2003
- 2003-01-29 AT AT08166881T patent/ATE463241T1/de active
- 2003-01-29 NZ NZ534452A patent/NZ534452A/en not_active IP Right Cessation
- 2003-01-29 PL PL372118A patent/PL211836B1/pl unknown
- 2003-01-29 CA CA2474479A patent/CA2474479C/en not_active Expired - Lifetime
- 2003-01-29 KR KR1020047011787A patent/KR100947168B1/ko not_active Expired - Lifetime
- 2003-01-29 BR BR0307193-6A patent/BR0307193A/pt not_active Application Discontinuation
- 2003-01-29 UA UA20040806416A patent/UA79445C2/uk unknown
- 2003-01-29 DE DE60332067T patent/DE60332067D1/de not_active Expired - Lifetime
- 2003-01-29 PT PT03703575T patent/PT1474117E/pt unknown
- 2003-01-29 ES ES03703575T patent/ES2321180T3/es not_active Expired - Lifetime
- 2003-01-29 EP EP03703575A patent/EP1474117B1/en not_active Revoked
- 2003-01-29 DE DE60326320T patent/DE60326320D1/de not_active Expired - Lifetime
- 2003-01-29 PT PT08166881T patent/PT2036549E/pt unknown
- 2003-01-29 JP JP2003563536A patent/JP2005521663A/ja not_active Withdrawn
- 2003-01-29 SI SI200331563T patent/SI1474117T1/sl unknown
- 2003-01-29 DK DK08166881.6T patent/DK2036549T3/da active
- 2003-01-29 DK DK03703575T patent/DK1474117T3/da active
- 2003-01-29 RU RU2004122921/15A patent/RU2301673C2/ru active
- 2003-01-29 WO PCT/SE2003/000156 patent/WO2003063842A1/en not_active Ceased
- 2003-01-29 CN CNB038031221A patent/CN1287774C/zh not_active Expired - Lifetime
- 2003-01-29 AT AT03703575T patent/ATE423552T1/de active
- 2003-01-29 US US10/502,685 patent/US7759328B2/en not_active Expired - Lifetime
- 2003-01-29 EP EP08166881A patent/EP2036549B1/en not_active Expired - Lifetime
- 2003-01-29 SI SI200331805T patent/SI2036549T1/sl unknown
- 2003-01-29 KR KR1020097024298A patent/KR20090125857A/ko not_active Ceased
- 2003-01-29 AU AU2003206289A patent/AU2003206289B2/en not_active Expired
- 2003-01-29 ES ES08166881T patent/ES2342509T3/es not_active Expired - Lifetime
-
2004
- 2004-07-21 IS IS7360A patent/IS7360A/is unknown
- 2004-07-22 IL IL163160A patent/IL163160A/en active IP Right Grant
- 2004-07-27 CO CO04071996A patent/CO5611098A2/es not_active Application Discontinuation
- 2004-07-28 MX MXPA04007295A patent/MXPA04007295A/es active IP Right Grant
- 2004-07-29 ZA ZA2004/06086A patent/ZA200406086B/en unknown
- 2004-08-19 NO NO20043458A patent/NO337006B1/no not_active IP Right Cessation
-
2009
- 2009-04-29 CY CY20091100471T patent/CY1109030T1/el unknown
-
2010
- 2010-02-26 JP JP2010041992A patent/JP5259636B2/ja not_active Expired - Lifetime
- 2010-05-28 US US12/790,196 patent/US8143239B2/en not_active Expired - Fee Related
- 2010-06-14 CY CY20101100546T patent/CY1110081T1/el unknown
-
2012
- 2012-03-05 US US13/411,939 patent/US8575137B2/en not_active Expired - Fee Related
-
2013
- 2013-04-16 IS IS9028A patent/IS2960B/is unknown
- 2013-10-18 US US14/057,548 patent/US20140286878A1/en not_active Abandoned
-
2015
- 2015-03-02 US US14/635,550 patent/US20160022703A1/en not_active Abandoned
-
2017
- 2017-02-08 US US15/427,425 patent/US10166247B2/en not_active Expired - Lifetime
-
2018
- 2018-08-22 US US16/108,368 patent/US20190216828A1/en not_active Abandoned
-
2020
- 2020-03-27 US US16/832,590 patent/US11311558B2/en not_active Expired - Lifetime
Cited By (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| KR20200024102A (ko) | 2018-08-27 | 2020-03-06 | 데이진 가부시키가이샤 | 극세 탄소 섬유 혼합물, 그 제조 방법, 및 탄소계 도전 보조제 |
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| KR100947168B1 (ko) | 흡입용 조성물 | |
| AU2003206289A1 (en) | Composition for inhalation | |
| EP2488157B1 (en) | Improved formulations | |
| HK1126684B (en) | Novel composition | |
| AU2013203244B2 (en) | Improved formulations | |
| HK1173076B (en) | Improved formulations | |
| HK1173076A (en) | Improved formulations |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| A107 | Divisional application of patent | ||
| PA0104 | Divisional application for international application |
Comment text: Divisional Application for International Patent Patent event code: PA01041R01D Patent event date: 20091123 |
|
| PG1501 | Laying open of application | ||
| A201 | Request for examination | ||
| PA0201 | Request for examination |
Patent event code: PA02012R01D Patent event date: 20091223 Comment text: Request for Examination of Application |
|
| E902 | Notification of reason for refusal | ||
| PE0902 | Notice of grounds for rejection |
Comment text: Notification of reason for refusal Patent event date: 20100107 Patent event code: PE09021S01D |
|
| E601 | Decision to refuse application | ||
| PE0601 | Decision on rejection of patent |
Patent event date: 20100310 Comment text: Decision to Refuse Application Patent event code: PE06012S01D Patent event date: 20100107 Comment text: Notification of reason for refusal Patent event code: PE06011S01I |